Irvine, CA (PRWEB) August 31, 2006
DataLabs, Inc., an innovative developer of Internet-based software applications for clinical development, settled its pending litigation related to Datasci’s U.S. Patent (Patent No. 6,496,827) concerning the collection and validation of clinical trial data. Under the terms of the settlement agreement, DataLabs has entered into a non-exclusive licensing arrangement on a going-forward basis.
The settlement has allowed DataLabs to continue focusing on innovative product development efforts and to provide each of its customers continued confidence in adopting any DataLabs product.
“DataLabs’ primary concern was the possibility of our customers being drawn into the suit,” said William E. Maya, DataLabs chief executive officer. “By quickly settling this pending litigation, each of our valued customers can be assured that all DataLabs products are free of any 827 patent issues.”
DataLabs is one of only two EDC vendors that have resolved the potential for litigation surrounding the 827 patent.
The case number for the above-mentioned pending patent litigation is US-DIS-MDD 8:06cv1815.
DataLabs is an innovative developer of Web-based applications for clinical development that helps the biopharmaceutical industries accelerate clinical trials with proven software for eClinical Data Management, eCollaboration, and eLearning. Based on Microsoft technology, XML Web services and CDISC ODM standards, the DataLabs eClinical Solution product suite adapts to established operating procedures and integrates easily with existing technology systems. As a result, DataLabs’ customers enjoy a low total cost of ownership and high return on investment. Major pharmaceutical companies, government entities, healthcare organizations and contract research organizations (CROs) are currently realizing time and cost savings using DataLabs eClinical Solutions. DataLabs, a Microsoft Gold Certified Partner, is based in Irvine, Calif. with U.S. East Coast offices in Pennsylvania and European offices in the United Kingdom. For more information, please visit http://www.datalabs.com.